...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Vaccine >Novel influenza virus vectors expressing Brucella L7/L12 or Omp16 proteins in cattle induced a strong T-cell immune response, as well as high protectiveness against B. abortus infection.
【24h】

Novel influenza virus vectors expressing Brucella L7/L12 or Omp16 proteins in cattle induced a strong T-cell immune response, as well as high protectiveness against B. abortus infection.

机译：在牛中表达布鲁氏菌L7 / L12或Omp16蛋白的新型流感病毒载体诱导了强烈的T细胞免疫应答，以及对流产双歧杆菌感染的高度保护。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

This paper presents the results of a study of the immunogenicity and protectiveness of new candidate vector vaccine against Brucella abortus - a bivalent vaccine formulation consisting of a mixture of recombinant influenza A subtype H5N1 or H1N1 (viral constructs vaccine formulation) viruses expressing Brucella ribosomal protein L7/L12 and Omp16, in cattle. To increase the effectiveness of the candidate vaccine, adjuvants such as Montanide Gel01 or chitosan were included in its composition. Immunization of cattle (heifers aged 1-1.5 years, 5 animals per group) with the viral constructs vaccine formulation only, or its combination with adjuvants Montanide Gel01 or chitosan, was conducted via the conjunctival method using cross prime (influenza virus subtype H5N1) and booster (influenza virus subtype H1N1) vaccination schedules at an interval of 28 days. Vaccine candidates were evaluated in comparison with the positive (B. abortus S19) and negative (PBS) controls. The viral constructs vaccine formulations, particularly in combination with Montanide Gel01 adjuvant promoted formation of IgG antibodies (with a predominance of antibodies of isotype IgG2a) against Brucella L7/L12 and Omp16 proteins in ELISA. Moreover, these vaccines in cattle induced a strong antigen-specific T-cell immune response, as indicated by a high number of CD4+ and CD8+ cells, as well as the concentration of IFN- gamma , and most importantly provided a high level of protectiveness comparable to the commercial B. abortus S19 vaccine and superior to the B. abortus S19 vaccine in combination with Montanide Gel01 adjuvant. Based on these findings, we recommended the bivalent vaccine formulation containing the adjuvant Montanide Gel01 for practical use in cattle.
机译：本文介绍了针对流产布鲁氏菌的新型候选载体疫苗的免疫原性和保护性的研究结果-一种由表达布鲁氏菌核糖体蛋白L7的重组A型H5N1或H1N1流感病毒混合物组成的二价疫苗制剂/ L12和Omp16（牛）。为了提高候选疫苗的有效性，佐剂如Montanide Gel01或壳聚糖被包含在其成分中。仅使用病毒构建体疫苗制剂或其与佐剂Montanide Gel01或壳聚糖结合的牛（1-1.5岁小母牛，每组5只动物）通过结膜方法使用交叉引物（H5N1型流感病毒）和每隔28天进行一次加强免疫（H1N1流感病毒亚型）疫苗接种计划。与阳性对照（流产双歧杆菌S19）和阴性对照（PBS）相比，评估了候选疫苗。病毒构建体疫苗制剂，特别是与Montanide Gel01佐剂的组合，可促进ELISA中针对布鲁氏菌L7 / L12和Omp16蛋白的IgG抗体（主要是同型IgG2a抗体）的形成。此外，牛中的这些疫苗可诱导强烈的抗原特异性T细胞免疫反应，大量CD4 + 和CD8 + 细胞以及浓度的IFN-γ，最重要的是提供了与商业流产双歧杆菌S19疫苗相当的高水平保护性，并且优于结合Montanide Gel01佐剂的流产双歧杆菌S19疫苗。基于这些发现，我们建议将含有佐剂Montanide Gel01的二价疫苗制剂用于牛中。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号